Trend > News > Breakingviews – European drug discounts will ruffle U.S. funder
Breakingviews – European drug discounts will ruffle U.S. funder
Breakingviews - European drug discounts will ruffle U.S. funder,Europe’s plan to slash prices on pharmaceutical drugs could set off tensions with the U.S. The European Union proposed on Wednesday a legislative overhaul of the sector across the 27-nation bloc. The European Commission is looking to slash the length of the exclusivity period benefiting drugmakers before generics can enter the market from 10 to eight years. This would incentivise drug makers like AstraZeneca and GSK to sell to all European countries at once. As it stands, drugmakers send drugs to wealthier countries like Germany first before knocking down the price for poorer nations. It takes only 133 days for German patients to access new medicines, against nearly two-and-a-half years for Romanians, according to the European Federation of Pharmaceutical Industries and Associations.

Breakingviews – European drug discounts will ruffle U.S. funder

Europe’s plan to slash prices on pharmaceutical drugs could set off tensions with the U.S. The European Union proposed on Wednesday a legislative overhaul of the sector across the 27-nation bloc. The European Commission is looking to slash the length of the exclusivity period benefiting drugmakers before generics can enter the market from 10 to eight years. This would incentivise drug makers like AstraZeneca and GSK to sell to all European countries at once. As it stands, drugmakers send drugs to wealthier countries like Germany first before knocking down the price for poorer nations. It takes only 133 days for German patients to access new medicines, against nearly two-and-a-half years for Romanians, according to the European Federation of Pharmaceutical Industries and Associations.